Welcome to our dedicated page for Akebia Therapeut news (Ticker: AKBA), a resource for investors and traders seeking the latest updates and insights on Akebia Therapeut stock.
Akebia Therapeutics Inc. (AKBA) is a biopharmaceutical company developing and commercializing treatments for kidney disease through hypoxia-inducible factor biology. The company's news flow typically includes clinical development updates, regulatory interactions, commercial milestones for its oral anemia therapy Vafseo (vadadustat), and financial results. Investors following Akebia track announcements related to product adoption in dialysis and non-dialysis settings, post-marketing study findings, and strategic developments in the nephrology market.
This news feed provides comprehensive coverage of material events affecting Akebia, including quarterly earnings releases, SEC filings, clinical trial data presentations, and regulatory updates. Biotech investors particularly monitor news about Vafseo's market penetration, physician adoption trends, and real-world evidence generation. The company's partnership announcements, investor presentations, and guidance updates offer insights into commercial execution and strategic priorities within the competitive renal anemia treatment landscape.
Track regulatory filings, clinical developments, and business updates that may influence Akebia's position in the kidney disease treatment market. The news archive includes announcements about inducement grants under Nasdaq listing rules, conference presentations to the investment community, and material events reported through Form 8-K filings. Bookmark this page to monitor developments in HIF-based therapies and Akebia's progress in establishing its nephrology franchise.
Akebia Therapeutics (Nasdaq: AKBA) announced that the first patient has been dosed in a Phase 2 randomized, double-blind, placebo-controlled study of oral once-daily praliciguat for biopsy-confirmed focal segmental glomerulosclerosis (FSGS).
The study will randomize ~60 adults on maximally tolerated ACEi/ARB therapy 1:1 to praliciguat or placebo for a 24-week double-blind period followed by a 24-week open-label extension. The primary endpoint is change in urine protein-to-creatinine ratio (UPCR) at Week 24; a key secondary endpoint is partial remission defined as 40% UPCR reduction and UPCR <1.5 g/g.
Akebia Therapeutics (Nasdaq: AKBA) granted inducement stock options to a newly hired employee on December 31, 2025 under Nasdaq Listing Rule 5635(c)(4).
The grant covers 197,900 options with an exercise price of $1.61 per share (equal to the closing price on the grant date). Options vest over four years (25% on the first anniversary, then quarterly thereafter), each option has a 10-year term, and awards are subject to Akebia’s inducement award program and a stock option agreement.
Akebia Therapeutics (Nasdaq: AKBA) granted inducement stock options to two newly hired employees on November 28, 2025 under Nasdaq Listing Rule 5635(c)(4).
The awards total 22,576 options with an exercise price of $1.58 per share (equal to the closing price on the grant date). Options vest over four years (25% at the first anniversary, then quarterly vesting for the remaining 75%), have a 10-year term, and are governed by Akebia’s inducement award program and stock option agreement.
Akebia (Nasdaq: AKBA) announced the establishment of a rare kidney disease pipeline on Dec 1, 2025, centered on two candidates: AKB-097 (a tissue-targeted C3d‑Factor H fusion protein complement inhibitor acquired from Q32 Bio) and praliciguat (an sGC stimulator).
Akebia acquired all rights to AKB-097 and says it targets complement activation sites without expected systemic complement inhibition. A Phase 2 trial of praliciguat in FSGS has been initiated, and both Phase 2 programs are planned to begin treating subjects in 2026. Akebia expects AKB-097 Phase 2 basket trial data beginning in 2027.
Q32 Bio (NASDAQ:QTTB) sold its Phase 2 complement inhibitor ADX-097 to Akebia Therapeutics (NASDAQ:AKBA) for $12 million in upfront and near-term payments and is eligible for up to $592 million in total milestone payments plus tiered royalties.
Q32 received $7M at signing, $3M at six months, and $2M by end of 2026 or upon an earlier milestone. The company says proceeds and existing cash are expected to extend its runway into the second half of 2027 while it advances bempikibart and SIGNAL-AA Part B topline data is on track for mid-2026. Q32 retains its tissue-targeted complement platform, including ADX-096, and is evaluating strategic options for remaining programs.
Akebia Therapeutics (Nasdaq: AKBA) said its executive team will participate in a Fireside Chat at the Piper Sandler 37th Annual Healthcare Conference on Tuesday, December 2, 2025 at 4:30 PM ET in New York City.
The company said a webcast of the presentation will be available after the conference via the Investors section at https://ir.akebia.com. The Piper Sandler conference runs December 2–4, 2025.
Akebia (Nasdaq: AKBA) reported Q3 2025 results and operational updates for Vafseo (vadadustat). Total revenues were $58.8 million in Q3 2025 versus $37.4 million in Q3 2024. Vafseo net product revenue was $14.3 million in Q3 2025; Auryxia net product revenue was $42.5 million.
Prescribing access across the customer base reached 60,000 patients by end of Q3 and is expected to grow to 275,000 patients by year-end. A DaVita operational pilot at >100 clinics is expected to complete in November 2025. A post-hoc INNO2VATE analysis presented at ASN Kidney Week showed a statistically more favorable composite of all-cause mortality and hospitalization for vadadustat versus ESA.
Q3 net income was $0.5 million versus a $20.0 million loss year-ago; cash and cash equivalents were $166.4 million as of September 30, 2025.
Akebia Therapeutics (Nasdaq: AKBA) presented a post-hoc win-odds analysis from the Phase 3 INNO2VATE dialysis trials at ASN Kidney Week on Nov 6, 2025 showing a statistically more favorable composite of all-cause mortality and hospitalization for patients receiving Vafseo (vadadustat) versus darbepoetin alfa. The analysis reported an inverted win-odds of 0.93 (95% CI 0.87–0.99; P=0.03) on study and 0.86 (95% CI 0.81–0.95; P<0.0001) on treatment plus 28 days. Vafseo is approved for dialysis-dependent CKD anemia and available in the U.S. since January 2025. The company noted ongoing real-world trials including VOICE to further measure mortality and hospitalizations.
Akebia Therapeutics (Nasdaq: AKBA) announced that CEO John P. Butler and Chief Financial and Chief Business Officer Erik Ostrowski will present at two investor conferences in November 2025. They will appear at the Guggenheim 2nd Annual Healthcare Innovation Conference in Boston on November 10, 2025 with a fireside chat at 3:00 PM EST, and at the Jefferies Global Healthcare Conference in London on November 17, 2025 with a fireside chat at 12:00 PM GMT.
A webcast of each presentation will be available through the Investors section of Akebia’s website at https://ir.akebia.com following the conferences.
Akebia Therapeutics (Nasdaq: AKBA) granted stock options to three newly hired employees on October 31, 2025 as inducement awards under Nasdaq Listing Rule 5635(c)(4). An aggregate of 51,825 options were issued with an exercise price of $2.21 per share, equal to the closing price on the grant date.
The options vest over four years (25% at the first anniversary, then quarterly for the remaining 75%), have a 10-year term, and are subject to Akebia’s inducement award program and stock option agreement, and to continued service requirements.
FAQ
What is the current stock price of Akebia Therapeut (AKBA)?
What is the market cap of Akebia Therapeut (AKBA)?
